Prognostic value of vascular endothelial growth factor (VEGF), VEGF receptor 2, platelet-derived growth factor-β (PDGF-β), and PDGF-β receptor expression in papillary renal cell carcinoma

Myong Kim, Mooyoung Sohn, Myungsun Shim, Seung Kwon Choi, Myungchan Park, Eunna Kim, Heounjeong Go, Yangsoon Park, Yong Mee Cho, Jae Y. Ro, In Gab Jeong, Cheryn Song, Jun Hyuk Hong, Choung Soo Kim, Hanjong Ahn

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

The prognostic value of the expression of vascular endothelial growth factor (VEGF), VEGF receptor 2 (VEGFR2), platelet-derived growth factor (PDGF)-β, and PDGF receptor (PDGFR)-β in papillary renal cell carcinoma (pRCC) is unknown. A total of 145 patients, who were confirmed to have pRCC, were analyzed. Expression levels of molecular markers were assessed via immunohistochemistry. The median follow-up period for all patients was 52.0 (interquartile range, 34.5-90.5) months. Among the cohort of 145 patients, high VEGF expression was observed in 100 (69.0%) patients, whereas high expression of VEGFR2, PDGF-β, and PDGFR-β was observed in 64 (44.1%), 42 (29.0%), and 30 (20.7%) patients, respectively. Only patients with high VEGFR2 expression exhibited improved 10-year recurrence-free survival (85.3% versus 58.1%; P = .005) and cancer-specific survival (86.4% versus 70.1%; P = .014) rates compared with individuals who exhibited low expression. Multivariate analysis revealed that high VEGFR2 expression was an independent prognostic factor for recurrence (hazard ratio, 0.326; P = .006) and cancer-specific mortality (hazard ratio, 0.334; P = .046). During follow-up, 17 patients received targeted drug therapy. Patients with high VEGFR2 expression showed a better initial response (partial response, 40%; stable disease, 20%; progressive disease, 40%) than patients with low expression did (partial response, 0%; stable disease, 58.3%; progressive disease, 41.7%; P = .052). pRCC with high VEGFR2 expression seems to be associated with a better initial response to targeted drug therapy and a better prognostic outcome.

Original languageEnglish (US)
Pages (from-to)78-89
Number of pages12
JournalHuman Pathology
Volume61
DOIs
StatePublished - Mar 1 2017

Keywords

  • Papillary renal cell carcinoma
  • Platelet-derived growth factor
  • Prognosis
  • Treatment response
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Prognostic value of vascular endothelial growth factor (VEGF), VEGF receptor 2, platelet-derived growth factor-β (PDGF-β), and PDGF-β receptor expression in papillary renal cell carcinoma'. Together they form a unique fingerprint.

Cite this